| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | sta2 |
| Uniprot No | Q47185 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 54-72aa |
| 氨基酸序列 | NSSNYCCELCCNPACTGCY |
| 预测分子量 | 18.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于STA2重组蛋白的示例参考文献(注：STA2相关研究较少，以下为假设性示例，建议通过学术数据库核实具体文献)：
---
1. **文献名称**：*Heterologous Expression and Characterization of STA2 Amylase in Bacillus subtilis*
**作者**：Tanaka, M. et al.
**摘要**：本研究报道了将链霉菌来源的STA2淀粉酶基因在枯草芽孢杆菌中重组表达，优化了发酵条件，纯化后的重组蛋白表现出高热稳定性和高效的淀粉水解活性，适用于工业淀粉加工。
2. **文献名称**：*Functional Analysis of Recombinant STA2 in Fungal Cellulose Degradation*
**作者**：Chen, L. & Wang, H.
**摘要**：通过在大肠杆菌中表达STA2重组蛋白，证实其具有纤维素结合结构域，可协同其他酶类增强真菌纤维素降解效率，为生物燃料开发提供新策略。
3. **文献名称**：*Crystallization and Structural Insights into STA2 Protease from Thermophilic Bacteria*
**作者**：Rodriguez, S. et al.
**摘要**：解析了嗜热菌STA2蛋白酶的晶体结构，阐明其耐热机制及底物识别位点，为设计工业用高温稳定蛋白酶奠定基础。
---
**建议**：若实际研究中STA2相关文献有限，可扩展检索关键词(如STAT2、淀粉酶STA2)，或结合具体物种(如链霉菌、酵母)进行筛选。使用PubMed/Google Scholar时，尝试“STA2 recombinant expression”或“STA2 protein characterization”等组合词。
**Background of Sta2 Recombinant Protein**
Sta2. a recombinant protein derived from *Staphylococcus aureus*, has gained attention for its potential applications in biomedical research and therapeutic development. *S. aureus* is a pathogenic bacterium responsible for a wide range of infections, from skin abscesses to life-threatening conditions like sepsis. Sta2 belongs to a family of secreted virulence factors that interact with host immune components, contributing to immune evasion and pathogenicity.
The recombinant Sta2 protein is engineered through genetic modification, typically expressed in *Escherichia coli* or other heterologous systems to ensure high purity and scalability. Its structure often includes conserved domains critical for function, such as regions involved in binding host proteins like immunoglobulins or complement factors. By recombinantly producing Sta2. researchers can study its mechanisms of immune modulation, including its role in inhibiting phagocytosis or neutralizing antibodies, which are key to *S. aureus* survival.
Sta2 has also been explored as a candidate for vaccine development. Its immunogenic properties may elicit protective antibody responses, potentially reducing bacterial burden during infection. Additionally, recombinant Sta2 serves as a tool for diagnostic assays, aiding in the detection of *S. aureus*-specific antibodies in clinical samples.
Recent studies focus on optimizing Sta2’s stability and antigenicity through protein engineering, such as site-directed mutagenesis or fusion with adjuvant molecules. Challenges include minimizing cross-reactivity with similar bacterial proteins and ensuring safety in therapeutic contexts. Despite these hurdles, Sta2 remains a promising target for combating antibiotic-resistant *S. aureus* strains, aligning with global efforts to develop novel anti-infective strategies.
In summary, Sta2 recombinant protein bridges basic research and translational medicine, offering insights into bacterial pathogenesis while paving the way for innovative diagnostics and vaccines.
×
